Bellevue Group AG Buys 13,654 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Bellevue Group AG boosted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 21.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 76,414 shares of the company’s stock after buying an additional 13,654 shares during the quarter. Bellevue Group AG’s holdings in Amneal Pharmaceuticals were worth $636,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Rothschild Investment LLC purchased a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $26,000. Gladius Capital Management LP bought a new stake in Amneal Pharmaceuticals during the third quarter worth $37,000. DekaBank Deutsche Girozentrale purchased a new position in Amneal Pharmaceuticals in the second quarter worth $42,000. nVerses Capital LLC bought a new position in Amneal Pharmaceuticals in the 2nd quarter valued at $62,000. Finally, Xponance Inc. purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at $65,000. 31.82% of the stock is currently owned by institutional investors.

Insider Activity at Amneal Pharmaceuticals

In related news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the sale, the senior vice president now directly owns 13,665 shares in the company, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 26.56% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. StockNews.com raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 11th. Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Truist Financial increased their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, October 2nd. Piper Sandler raised their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective on the stock in a research note on Friday, September 6th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Stock Down 1.0 %

NASDAQ AMRX opened at $8.27 on Monday. The company has a market cap of $2.56 billion, a PE ratio of -12.16 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a 52 week low of $4.17 and a 52 week high of $9.48. The firm’s 50-day simple moving average is $8.52 and its two-hundred day simple moving average is $7.79.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.